Inventor · disambiguated record
Drake Laface
Also filed as: LAFACE DRAKE · LAFACE DRAKE M · LAFACE DRAKE MAURICE
8 granted patents·17 pending applications·121 citations·filing 1999–2025
85Inventor score
Top patents by PatentIndex Score
25 records- 0194US10618958B2Anti-TIGIT antibodiesMERCK SHARP & DOHME·Filed 2017·Granted Apr 14, 2020·10 cites·32 claims
- 0286US2025064924A1Anti-tigit antibodiesMERCK SHARP & DOHME LLC·Filed 2024·Application pending·0 cites
- 0384US12102680B2Anti-TIGIT antibodiesMERCK SHARP & DOHME LLC·Filed 2020·Granted Oct 1, 2024·1 cites·30 claims
- 0484US7001770B1Calpain inhibitors and their applicationsCANJI INC·Filed 1999·Granted Feb 21, 2006·78 cites·19 claims
- 0574US6464976B1Methods and compositions for reducing immune responseCANJI INC·Filed 2000·Granted Oct 15, 2002·7 cites·4 claims
- 0668US6649158B1Methods and compositions to induce antitumor responseCANJI INC·Filed 1999·Granted Nov 18, 2003·25 cites·5 claims
- 0765US2007244064A1Methods and compositions to induce antitumor responseCANJI INC·Filed 2006·Application pending·0 cites
- 0863US8178094B2Methods for inhibiting tumor growth or reducing metastatic burden in a subject by administering FDF03 antibodiesBIGLER MICHAEL E·Filed 2008·Granted May 15, 2012·0 cites·14 claims
- 0963US2007128159A1Chemokines as adjuvants of immune responseSCHERING CORP·Filed 2007·Application pending·0 cites
- 1060US2025289890A1Anti-cancer combination therapies comprising ctla-4 and pd-1 blocking agentsMERCK SHARP & DOHME LLC·Filed 2025·Application pending·0 cites
- 1158US2004022769A1Methods and compositions to induce antitumor responseFiled 2003·Application pending·0 cites
- 1257US9284377B2MDL-1 ligandMERCK SHARP & DOHME·Filed 2015·Granted Mar 15, 2016·0 cites·5 claims
- 1357US2017198042A1Anti-tigit antibodiesMERCK SHARP & DOHME·Filed 2017·Application pending·0 cites
- 1457US2008107629A1Methods and compositions for gene therapyCANJI INC·Filed 2007·Application pending·0 cites
- 1555US2015104453A1Fdf03 antibodies and uses thereofBIGLER MICHAEL E·Filed 2014·Application pending·0 cites
- 1654US2016068597A1Fdf03 antibodies and uses thereofMERCK SHARP & DOHME·Filed 2015·Application pending·0 cites
- 1753US2012258110A1Fdf03 antibodies and uses thereofBIGLER MICHAEL E·Filed 2012·Application pending·0 cites
- 1852US12358986B2Anti-cancer combination therapies comprising CTLA-4 and PD-1 blocking agentsMERCK SHARP & DOHME LLC·Filed 2020·Granted Jul 15, 2025·0 cites·5 claims
- 1952US2016355589A1Anti-tigit antibodiesWILLIAMS SYBIL M G·Filed 2015·Application pending·0 cites
- 2052US2013156771A1Fdf03 antibodies and uses thereofBIGLER MICHAEL E·Filed 2013·Application pending·0 cites
- 2149US2014227719A1Mdl-1 ligandMERCK SHARP & DOHME·Filed 2012·Application pending·0 cites
- 2249US2002187143A1Methods and compositions for reducing immune responseFiled 2002·Application pending·0 cites
- 2344US2008089890A1Methods of polypeptide productionCANJI INC·Filed 2007·Application pending·0 cites
- 2444US2022340660A1Biomarkers for anti-tigit antibody treatmentMERCK SHARP & DOHME·Filed 2019·Application pending·0 cites
- 2533US2013323246A1Use of mdl-1 antagonists to treat spondylarthropathyCUA DANIEL J·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Drake Laface files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →